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Background: The European Randomised Study of Screening for Prostate Cancer
(ERSPC) applies a prostate-specific antigen (PSA) cut-off value 3.0 ng/ml as an
indication for lateralised sextant biopsy.
Objective: To analyse the incidence and disease-speciﬁc mortality for prostate
cancer (PCa) in men with an initial PSA <3.0 ng/ml.
Design, setting and participants: From November 1993 to December 1999, a total
of 42 376 men identiﬁed from population registries in the Rotterdam region
(55–74 yr of age) were randomised to an intervention or control arm. A total of
19 950 men were screened during the ﬁrst screening round.
Intervention: A PSA <3.0 ng/ml was below the biopsy threshold. PCa cases were
identiﬁed at rescreens every 4 yr or as interval cancers.
Measurements: Distribution of incidence, aggressiveness, and disease-speciﬁc
mortality of PCa per PSA range was measured. Causes of death were evaluated by
an independent committee, and follow-up was complete until 31 December 2008.
Results and limitations: From 1993 to 2008, 915 PCa cases were diagnosed in 15
758 men (5.8%) with an initial PSA<3.0 ng/ml and amedian age of 62.3 yr. Median
overall follow-up was 11 yr. PCa incidence increased signiﬁcantly with higher
initial PSA levels. Aggressive PCa (clinical stage T2c, Gleason score 8, PSA
>20 ng/ml, positive lymph nodes, or metastases at diagnosis) was detected in
66 of 733 screen-detected PCa cases (9.0%) and 72 of 182 interval-detected PCa
cases (39.6%). Twenty-three PCa deaths occurred in the total population (0.15%),
with an increasing risk of PCa mortality in men with higher initial PSA values.
Conclusions: The risk of PCa, aggressive PCa and PCa mortality in a screening
population with initial PSA <3.0 ng/ml increases signiﬁcantly with higher initial
PSA levels. These results contribute to the risk stratiﬁcation and individual
management of men in PSA-based screening programmes.
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After first being described in 1979 [1], prostate-specific
antigen (PSA) became available as a biomarker [2] and
potential screening tool for the early detection of prostate
cancer (PCa) [3]. With PCa being the most frequent cancer
diagnosed in men and playing an important role in cancer-
related deaths worldwide [4,5], randomised studies set up
to determine whether PSA-based screening can reduce the
PCa-specific mortality [6,7] address an important health
issue. In fact, results of the European Randomised Study
of Screening for Prostate Cancer (ERSPC) have shown that
PSA-based screening can decrease PCa mortality by up to
30% [6,8].
However, despite the value of PSA in terms of lowering
PCamortality, its use in screening is limited as a result of its
lack of specificity in lower PSA ranges [9]. Since 1997, the
ERSPC has used a PSA value 3.0 ng/ml as an indication for
biopsy. To assess the risk of applying this cut-off value, we
analysed the data of men with initial PSA levels <3.0 ng/ml
in the Rotterdam section of the ERSPC and evaluated PCa
incidence and disease-specific mortality stratified by PSA
group.
2. Methods
From November 1993 to December 1999, a total of 42 376men 55–74 yr
of age identiﬁed in the Rotterdam population registry were randomised
to an intervention or a control arm. During the ﬁrst screening round, 19
950menwere screened (excludingmen previously diagnosed with PCa),
with lateralised sextant biopsies being initially recommended for an
abnormal digital rectal examination (DRE) or PSA level4.0 ng/ml. From
May 1997 on, DRE was abandoned as a screening test, and a PSA level
3.0 ng/ml was applied to recommend biopsies. Men diagnosed during
the ﬁrst screening round were excluded from this study to focus on the
risk of being diagnosed with PCa during follow-up.
During the second screening round (November 1997 to December
2003), two side studies were carried out. The ﬁrst side study (November
1997 to April 2001) provided a biopsy indication for men who doubled
their PSA at the second screening in the PSA range of 1–3 ng/ml. The
second side study (April 2001 to August 2002) investigated the positive
predictive value (PPV) and detection rate in men with PSA values of
2.0–3.9 ng/ml. The third round started in November 2001 and concluded
in December 2007; the fourth round started in November 2005 and is
ongoing. Another side study was carried out (September 2007 to
February 2009), providing a biopsy indication formenwith a PCa antigen
3 score10. The cancers found in the side studies are considered screen-
detected in the context of this report. Total PSA was measured with the
use of Hybritech assay systems (Beckman-Coulter, Fullerton, CA, USA),
and a 4-yr screening interval was used. Follow-up of PCa cases and
causes of death was carried out as previously described [10,11]. Data
were complete for a total period of 15 yr (December 1993 to December
2008).
Aggressive cancerwas deﬁned as clinical stage T2c, PSA at diagnosis
>20 ng/ml, or Gleason score 8, according to the D’Amico criteria [12],
next to positive lymph nodes or distant metastases at diagnosis.
Comorbidity at study entry was evaluated by assigning a Charlson score
to each subject based on an independently completed questionnaire on
medical history. For the purpose of this study, cases were scored as no
(Charlson score = 0), mild (Charlson score = 1), or severe (Charlson score
>2) comorbidity. Interval cancers were deﬁned as all cancers detected
clinically (either triggered by lower urinary tract symptoms, symptom-atic disease, or opportunistic screening) during a screening interval or
after reaching the 75-yr age limit.
The number of PCa cases, overall deaths, and disease-speciﬁc deaths
classiﬁed by PSA group (<1.0 ng/ml, 1.0–1.9 ng/ml, or 2.0–2.9 ng/ml)
and number per 1000 life years (LY) were recorded as well as the tumour
characteristics (Gleason score and TNM classiﬁcation) at diagnosis. Cox
regression analysis was used to determine PCa incidence, overall
survival (OS), and disease-speciﬁc survival (DSS) adjusted for age and
comorbidity and classiﬁed by PSA group. For incidence, the duration of
follow-up from ﬁrst screening to whatever came ﬁrst of diagnosis, death,
or censor date was calculated. For survival, time from ﬁrst screening to
either death or censor date was used. The proportional hazard
assumption was tested and found to be applicable, using log–log
survival curves. OS and DSS were assessed using the Kaplan-Meier
method. Statistical analyses were performed using SPSS v.17.0 (SPSS,
Chicago, IL, USA). All statistical tests were two-sided, and a p value<0.05
was considered statistically signiﬁcant.
3. Results
A total of 21 210 men were randomised to the screening
group, of which 19 950 men were actually screened. An
initial PSA value <3.0 ng/ml was measured in 15 837 men.
The population used for this analysis consisted of 15 758
men (15 837–79 first-round PCa). The number of detected
cancers per screening round and interval is indicated in
Fig. 1. From 1993 to 2008, a total of 915 PCa cases were
diagnosed in 15 758 men. Of these, 733 were screen-
detected and 182 were interval-detected cases, of which
63 men (34.6%) were diagnosed when they were 75 yr
or age or older. Median follow-up amounted to 11.1 and
11.5 yr overall and for PC cases, respectively. Median age of
the study population at baseline PSA measurement was
62.3 yr of age. Study population characteristics are provided
in Table 1.
Themedian baseline PSA level was 1.8 (25–75p; 1.2–2.4)
for men who developed PCa and 1.0 (25–75p; 0.6–1.6) for
men who did not (p < 0.001). At diagnosis, the median PSA
level for screen-detected cases (3.5, 25–75p; 2.9–4.6) and
interval-detected cases (8.1, 25–75p; 4.7–18.0) differed
significantly (p < 0.001).
In this study population, 5.8% (915 of 15 758) of all men
were diagnosed with PCa at a median of 7.1 yr after initial
PSA screening. The risk of PCa diagnosis increased from 1.7
per 1000 LY in men with PSA levels <1.0 ng/ml to 14.5 per
1000 LY in men with PSA levels of 2.0–2.9 ng/ml. The
cumulative hazard of being diagnosed with PCa showed a
4.0- and 10.3-fold increased risk for PSA groups 1.0–1.9
and 2.0–2.9 ng/ml, respectively, compared to PSA group
<1.0 ng/ml (p < 0.001; Fig. 2). Aggressive cancer was
present in 138 cases at diagnosis. Clinical stage and Gleason
score were unknown in 5 and 41 cases, respectively.
Tumour characteristics classified by PSA group are listed in
Table 2. The cumulative hazard of being diagnosed with
aggressive PCa was found to be statistically different
( p < 0.001), showing 2.7- and 6.2-fold increased risk for
PSA groups 1.0–1.9 and 2.0–2.9 ng/ml, respectively,
compared to PSA group <1.0 ng/ml (Fig. 3). To evaluate
the influence of biopsiedmen per category, we corrected for




- 7 interval PCa cases 
Interval 2 
Years 4–8 
Eligible for third screening 
n = 7099 (45.7%) 
Biopsied 
n = 1204 (7.6%)
Interval 3 
Years 8–12 
Eligible for fourth screening 
n = 1222 (7.7%) 
Biopsied 
n = 432 (2.7%)
- 68 interval PCa cases 
- 214 PCa cases at 
third screening 
- 36 PCa cases in side 
studies
- 86 interval PCa cases 
- 50 PCa cases at 
fourth screening 
- 37 PCa cases in side 
studies
Randomised to screening 
n = 21 210 
Screened 
n = 19 950 (94.1%)
PSA <3.0 ng/ml 
n = 15 837 (79.4%)
Interval 1 
Years 1–4 
Eligible for second screening 
n = 11 000 (69.5%) 
Biopsied
n = 1764 (11.1%)
- 79 PCa cases at 
initial screening 
(916 biopsies) 
- 13 PCa cases at early 
rescreening 
- 21 interval PCa 
- 275 PCa cases at 
repeat screening 
- 108 PCa cases in side 
studies
Fig. 1 – Consort flow chart showing prostate cancer detection during screening rounds and intervals of men initially presenting with prostate-specific
antigen levels <3.0 ng/ml in the Rotterdam section of the European Randomised Study of Screening for Prostate Cancer.
PSA = prostate-specific antigen; PCa = prostate cancer.
Table 1 – Characteristics of the study population classified by prostate-specific antigen group
Characteristic PSA (ng/ml) Total study population
<1.0 1.0–1.9 2.0–2.9
Subjects, No. (%) 7126 (45.2) 6156 (39.1) 2476 (15.7) 15 758 (100)
Median age at initial PSA test, yr 61.2 62.8 64.3 62.3
Charlson score, No. (%)
0 5189 (72.8) 4579 (74.4) 1820 (73.5) 11 588 (73.5)
1 1638 (23.0) 1319 (21.4) 545 (22.0) 3502 (22.2)
2 266 (3.7) 208 (3.4) 93 (3.8) 567 (3.6)
Unknown 33 (0.5) 50 (0.8) 18 (0.7) 101 (0.6)
PCa, No. (per 1000 LY) 129 (1.7) 415 (6.4) 371 (14.5) 915 (5.5)
Aggressive PCa*, No. (per 1000 LY) 27 (0.36) 61 (0.94) 50 (1.95) 138 (0.83)
Median age at diagnosis, yr 69.5 68.9 68.2 68.8
Median time to diagnosis, yr 8.3 8.1 4.2 7.1
Overall deaths, No. (per 1000 LY) 1560 (20.8) 1365 (21.1) 610 (23.8) 3535 (21.4)
PCa deaths, No. (per 1000 LY) 3 (0.04) 11 (0.17) 9 (0.35) 23 (0.14)
PSA = prostate-speciﬁc antigen; PCa = prostate cancer; LY = life years.
* Deﬁned as clinical stage T2c, Gleason-score 8, PSA >20 ng/ml, positive lymph nodes, or distant metastasis at diagnosis.
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Fig. 2 – Risk of prostate cancer diagnosis corrected for age and stratified by prostate-specific antigen group.
PSA = prostate-specific antigen.
E U RO P E AN URO LOG Y 5 9 ( 2 0 1 1 ) 4 9 8 – 5 0 5 501biopsied. This resulted in hazard ratios (HRs) of 2.1 and 3.3
for PCa incidence and 2.0 and 3.3 for aggressive PCa in the
1.0–1.9- and 2.0–2.9-ng/ml PSA groups, respectively,
preserving their highly significant outcome.
Interval-detected PCa cases were aggressive more often
(72 of 182; 39.6%) than screen-detected cases (66 of 733;
9.0%; p < 0.001; Table 3). Of the interval-detected cases, 39
(21.4%) subjects were 75 yr of age or older.
The number of overall deaths and disease-specific deaths
classified by PSA group is outlined in Table 1. After a 15-yr
period, an overallmortality rate of 21.4menper 1000 LYwas
observed (3535 of 15 758; 22.4%), while PCa-specific
mortality reached 0.14 per 1000 LY (23 of 15 758; 0.15%).
The risk of PCa-specific mortality increased with higher
initial PSA levels from0.04 per 1000 LY in the PSA range<1.0
ng/ml to an incidence of 0.35per 1000 LY in the range 2.0–2.9
ng/ml. PCa-specific survival stratified by PSA group and
corrected for age and comorbidity is shown in Fig. 4. There










<1.0 7126 (45.2) 129 (1.8) 83 (64.3)
1.0–1.9 6156 (39.1) 415 (6.7) 276 (66.5)
2.0–2.9 2476 (15.7) 371 (15.0) 243 (65.5)
Total 15 758 (100) 915 (5.8) 602 (65.8)
PSA = prostate-speciﬁc antigen; PCa = prostate cancer.
* Deﬁned as clinical stage T2c, Gleason score 8, PSA >20 ng/ml, positive lympand 7.6 times higher for the PSA groups 1.0–1.9 and 2.0–2.9
ng/ml, respectively, than for the group PSA <1.0 ng/ml.
Disease-specific mortality occurred in 5 of 733 (0.7%)
screen-detected cases and in 18 of 182 (9.9%) interval-
detected cases (p < 0.001; Table 4). OS was higher in men
with initial PSA levels of 1.0–1.9 ng/ml (HR: 0.9; p = 0.026)
compared to the lowest PSA range (Fig. 5). All HRs are
provided in Table 3. For our cohort, the 5-yr, 10-yr, and 15-yr
OS rates were 92.7%, 82.2%, and 67.9%, respectively; the
PCa-specific survival rates were 100%, 99.9%, and 99.7%,
respectively.
4. Discussion
Results of the ERSPC have shown that early detection
by PSA-based screening can decrease PCa mortality up to
30% after a median follow-up of 9 yr [6,8]. The Go¨teborg
screening study, which is part of ERSPC, recently showed













42 (32.6) 76 (58.9) 47 (36.4) 27 (20.9)
132 (31.8) 310 (74.7) 89 (21.4) 61 (14.7)
122 (32.9) 279 (75.2) 73 (19.7) 50 (13.5)
296 (32.3) 665 (72.7) 209 (22.8) 138 (15.1)
h nodes, or distant metastasis at diagnosis.
[()TD$FIG]
Fig. 3 – Risk of aggressive prostate cancer corrected for age and stratified by prostate-specific antigen group.
PSA = prostate-specific antigen.
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PSA levels below commonly used thresholds, with PSA
lacking specificity, especially in these lower ranges [9]. This
study was set up to quantify the predictive value of a
negative result in PSA-based screening, to evaluate the risk
of postponing PCa diagnosis in screening by applying a PSA
cut-off 3.0 ng/ml, and to contribute to the understanding
of the natural history of PCa present in the low PSA ranges.
We identified a significant increase in PCa incidence in
menwith initial PSA values of 1.0–1.9 ng/ml and 2.0–2.9 ng/
ml of 4.0- and 10.3-fold, respectively, compared to men
with initial PSA levels <1.0 ng/ml. Similar results were
observed for aggressive PCa, which showed a 2.7- and 6.2-
fold increased risk in these groups, respectively. When
we examined alternative definitions of aggressive PCa
(ie, Gleason score 8 or PSA at diagnosis >20 ng/ml), the
overall patterns held, with higher PSA levels being
associated with higher risk. If we apply the PPV of 21.9%,
as was reported from the control arm of the Prostate Cancer
Prevention Trial [9] in 5587 biopsied men with initial PSA
3.0 ng/ml (>55 yr of age) receiving biopsies uponTable 3 – Hazard ratios for prostate cancer (PCa), aggressive PCa, and










PSA = prostate-speciﬁc antigen; PCa = prostate cancer; CI = conﬁdence interval.
* Reference group.indication (PSA >4.0 ng/ml or abnormal DRE) or at the
end of a 7-yr study, a total of 3468 PCa diagnoses would be
expected in 15 837men. This conclusion indicates that 2474
PCa cases were not (yet) diagnosed in our cohort. The
absence of PSA and clinical progression after 11 yr of follow-
up is reassuring, but longer observation periods are needed
to judge the natural history of these biopsy-detectable
cancers. Our data show that in particular, subjects with PSA
values close to the PSA cut-off have a high probability of
being diagnosed with PCa in subsequent rounds. Previous
studies confirm the association of PSA ranges with PCa by
showing a gradual increase in the odds of cancer during
follow-up with higher baseline PSA measurements [14,15].
In total, 3535 subjects died, resulting in an overall
mortality rate of 21.4 per 1000 LY. The slightly higher OS in
the group with an initial PSA level of 1.0–1.9 ng/ml
compared to the PSA <1.0 group remains unexplained.
The overall risk of PCa death in our study cohort was
limited, with a death rate equal to 0.14 per 1000 LY,
compared to 1.55 per 1000 LY (p < 0.001) for men with an
initial PSA value 3.0 ng/ml (11-fold higher) and 0.49 perdisease-specific mortality, adjusted for age and comorbidity score









( p = 0.003)
[()TD$FIG]
Fig. 4 – Cumulative disease-specific survival corrected for age and comorbidity and stratified by prostate-specific antigen group.
PSA = prostate-specific antigen.
E U RO P E AN URO LOG Y 5 9 ( 2 0 1 1 ) 4 9 8 – 5 0 5 5031000 LY in the overall cohort. A significant increase in the
risk of PCa-related death was observed with increasing
initial PSA, leading to 4.0- and 7.6-fold higher risks in the
1.0–1.9 ng/ml and 2.0–2.9 ng/ml PSA groups, respectively.
Interval-detected PCa had a substantial part in the incidence[()TD$FIG]
Fig. 5 – Cumulative overall survival corrected for age and com
PSA = prostate-specof aggressive PCa and disease-specific deaths. Further study
on how to prevent these interval cases is warranted,
because shortening the screening interval does not seem to
solve the matter but is rather likely to increase overdiagno-
sis, as was previously shown [16].orbidity and stratified by prostate-specific antigen group.
ific antigen.
Table 4 – Number of prostate cancer (PCa), aggressive PCa and disease-specific deaths in screen-detected and interval-detected cases
classified by prostate-specific antigen group
PSA (ng/ml) Men, No. (%) PCa, No. (% of PSA group) Aggressive PCa*, No.
(% of screening- or
interval-detected PCa)
PCa deaths, No.
(% of screening- or
interval-detected PCa)
Screening Interval Screening Interval Screening Interval
<1.0 7126 (45.2) 92 (1.3) 37 (0.5) 11 (12.0) 16 (43.2) 0 (0) 3 (8.1)
1.0–1.9 6156 (39.1) 345 (4.8) 53 (0.7) 29 (8.4) 32 (60.4) 4 (1.2) 7 (13.2)
2.0–2.9 2476 (15.7) 296 (4.2) 48 (0.7) 26 (8.8) 24 (50.0) 1 (0.3) 8 (16.7)
Total 15 758 (100) 733 (4.7) 182 (2.6) 66 (9.0) 72 (39.6) 5 (0.7) 18 (9.9)
PSA = prostate-speciﬁc antigen; PCa = prostate cancer.
* Deﬁned as clinical stage T2c, Gleason-score 8, PSA >20 ng/ml, positive lymph nodes, or distant metastasis at diagnosis.
E U RO P E AN URO LOGY 5 9 ( 2 0 1 1 ) 4 9 8 – 5 0 5504Our results are consistent with previous studies showing
PSA to be a predictor of death from PCa, even at moderate
PSA levels [17,18]. Vickers et al. [19] reported comparable
findings to ours from their cohort of unscreened men,
showing that PCa deaths among men with initial PSA levels
<1.0 ng/ml are rare. Results of the current study strengthen
the justification of the use of PSA in risk stratification for
screening purposes. The favourable outcome in men with
PSA values <1.0 ng/ml supports the result of a previous
study [20] to prolong the screening interval to 8 yr in this
group. To contribute to decreasing PCa mortality by means
of screening, a large number of PCa deaths would need to be
prevented, which cannot be found in the low PSA ranges.
More aggressive screening would lead to an unacceptable
number needed to investigate (NNI) and number needed to
treat (NNT). In line with this conclusion, a recent study [21]
showed an NNI of 24 642 and an NNT of 724 for PSA values
<2.0 ng/ml and in addition reveals excessive overdiagnosis
and minor profit in PCa mortality of only 0.005 per 1000 LY
between a screening cohort and a population-based cohort.
Our results support the justification of a PSA threshold for
screening based on current knowledge. Further effort
should focus on the 2.0–2.9-ng/ml PSA range.
Obviously, mechanisms to selectively detect aggressive
cancers are needed, because the increase in the PCa
detection rate with higher baseline PSA values does not
alter the fact that the greater part of cases does not harbour
aggressive disease. Already now, risk-stratification instru-
ments are available that avoid unnecessary biopsies and
decrease overdiagnosis by incorporating clinically available
risk modifiers and, once potentially indolent cancers are
diagnosed, unnecessary treatments [22,23]. In addition,
further study on molecular and genetic markers selectively
identifying aggressive disease is warranted.
5. Conclusions
This study provides insight into the natural history of PCa
cases that remain undetected and the fate of screening-
and interval-detected PCa in men with initial PSA values
<3.0 ng/ml. It was shown that the risk of developing PCa
and aggressive PCa as well as PCa-specific death in men
participating in a screening trial with an initial PSA value
<3.0 ng/ml significantly increases in patients with higher
initial PSA values. Interval-detected cancers more oftenhave aggressive characteristics and a substantial influence
in causing disease-specific death, although the overall risk
of PCa death in this cohort is low compared to men with
initial PSA values3.0 ng/ml (11-fold higher) and compared
to the risk of other causes of death (150-fold higher). These
results contribute to the risk stratification and individual
management of men in PSA-based screening programmes.
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